

Biotech Beat NVIDIA in 2025. Can It Do It Again?
Big pharma and biotech take the earnings stage this week with reports from Eli Lilly (NYSE: LLNY) and Novo Nordisk (NYSE: NVO) leading the lineup. Will they help the industry once again outperform AI champ NVIDIA (NASDAQ: NVDA), as the industry did in 2025? Karl Thiel, Tom King, and Tim Beyers discuss: - Slow rolling…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Motley Fool Hidden Gems Investing →
Big Tech Reports… And Eli Lilly’s Letdown 10/30/24

#273: Is Novo Nordisk a Buy? An Undervalued Stock or Falling Knife?

MM #224 Eli Lilly - Trillion $ Health Company?, Apple’s Competition, NVIDIA & Ian's Invest Fest Presentation

Guide to the AI Barnyard, Eli Lilly Hits $1T Valuation, Has AI Ruined the Em Dash? | Julia Steinberg, Bobby Ghoshal
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.


